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Constipation kills
 
Cellular constipation can be
deadly, according to a study on
page 1587. Wang and colleagues
show that cells get clogged
with aborted secretory cargo
when they lack an enzyme that
helps form vesicles. Deletion of
this enzyme proved lethal in
mice, halting brain, bone and
vascular development.
The enzyme in question is
a protein tyrosine phosphatase (PTP) called MEG2. MEG2 binds
lipids and resides on intracellular vesicle membranes, where it
clips phosphate residues from the fusion protein NSF. Once dephos-
phorylated, NSF initiates homotypic fusion between immature
secretory vesicles, a critical step in protein secretion.
Knocking out MEG2, the team found, prevented T cells
(isolated from chimeric mice) from secreting the autocrine growth
factor interleukin-2, stunting T cell proliferation in response to
stimulation. Electron micrographs of the deficient T cells revealed
that the cells lacked mature secretory vesicles and were clogged
with the dense remains of fusion-incompetent vesicles.
Platelets that lacked MEG2 were also dysfunctional, failing to
aggregate when exposed to the clotting factor thrombin. But the
MEG2 defect spared neutrophils and macrophages, although these
cells rely on the same cellular machinery for vesicle release.
Cell type–specific PTPs might compensate for MEG2’s absence
in neutrophils and macrophages. Besides looking for these PTPs, the
group is also investigating the mechanism behind the developmental
defects in the MEG2-deficient mice, which they suspect result from
an inability to produce growth factors that direct the migration and
differentiation of progenitor cells. 
Mature secretory vesicles (arrows) 
are missing in the absence of the 
phosphatase MEG2.
 
Suppressive CpG
 
A study by Hessel et al. (page 1563) explains how a 
potent immune activator shuts down allergic 
inflammation. CpG-rich DNA sequences, common in 
microbial DNA, are best known as agents that bind to 
the innate receptor Toll-like receptor (TLR)-9 on 
immune cells, triggering their activation and alerting 
the host to the pathogenic invasion.
Clinicians have taken advantage of the immune-
activating qualities of CpG-rich DNA molecules, which are 
in a clinical trial as immunostimulatory agents such as 
adjuvants. However, treatment with these synthetic DNAs 
also inhibits allergic airway inflammation in mice, a 
phenomenon commonly attributed to the CpG-induced 
production of T helper (Th)-1–promoting cytokines, which 
counteract the effects of allergy-promoting Th2 cytokines.
But Hessel and colleagues now show that antiallergy 
CpG DNA treatment works not by antagonizing the effects 
of Th2 cytokines, but by preventing the Th2 response from 
ever getting started. CpG treatment inhibited the early 
production of the Th2 cytokine interleukin-4 from 
basophils and mast cells, and crippled the function of lung 
dendritic cells (DCs). DCs from CpG-treated mice had 
reduced levels of MHC class II and costimulatory 
molecules and were thus unable to activate Th2 cells. 
These results were unexpected as, in most contexts, CpG 
treatment increases the expression of these molecules on 
DCs—the basis for its efficacy as a vaccine adjuvant.
What determines whether CpG sequences will activate 
or inhibit DCs remains an open question, and one that will 
be important to resolve in order to ensure that CpG DNAs—
now also in clinical trials as asthma inhibitors—generate 
the desired response in humans. 
 
No entry for adenosine
 
The body has evolved a variety of ways to limit the destructive 
effects of low oxygen, one of which is to ramp up extracellular 
levels of the nucleoside adenosine. High extracellular adenosine 
limits hypoxia-driven vascular leakage by promoting the barrier 
function of endothelial cells and helps dampen inflammatory 
responses by inhibiting immune cell activation and cytokine 
production. Now, on page 1493, Eltzschig and colleagues find that 
hypoxia keeps extracellular adenosine high by switching off 
production of its cellular importer.
How the body accumulates extracellular adenosine, which is 
normally pumped rapidly back into cells by equilibrative nucleoside 
transporters (ENTs), is not completely clear. Hypoxia increases the 
expression of cell surface enzymes that hydrolyze ATP to adenosine 
and also increases the expression of adenosine receptors. But 
neither of these facts explains how extracellular adenosine avoids 
being rapidly shuttled back into cells by the ENT transporters.
Hypoxia increases extracellular ade-
nosine by shutting off the production 
of the adenosine transporter ENT1.
 
Eltzschig and colleagues 
now show that hypoxia 
dampens the transcription 
of ENT1, which encodes 
the primary transporter 
of adenosine in endothelial 
cells, thereby decreasing 
the cell’s adenosine 
importing capacity. The 
transcription factor HIF-1
 
 
 
 
(hypoxia inducible factor-
1
 
 
 
) bound to the ENT1 
promoter and was required 
for the repressive effect. The authors are now investigating how 
HIF-1
 
 
 
, best known for its ability to induce gene expression, shuts 
down the expression of ENT1. 
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